Literature DB >> 19366369

Erythropoiesis stimulating agents have limited therapeutic activity in transfusion-dependent patients with primary myelofibrosis regardless of serum erythropoietin level.

Jocelin Huang, Ayalew Tefferi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19366369     DOI： 10.1111/j.1600-0609.2009.01266.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN： 0902-4441            Impact factor:   2.997


× No keyword cloud information.
  21 in total

Review 1.  Future therapies for the myeloproliferative neoplasms.

Authors:  Robyn Scherber; Ruben A Mesa
Journal:  Curr Hematol Malig Rep       Date:  2011-03       Impact factor: 3.952

Review 2.  The underappreciated risk of thrombosis and bleeding in patients with myelofibrosis: a review.

Authors:  Devendra Kc; Lorenzo Falchi; Srdan Verstovsek
Journal:  Ann Hematol       Date:  2017-08-14       Impact factor: 3.673

3.  Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet.

Authors:  Tiziano Barbui; Giovanni Barosi; Gunnar Birgegard; Francisco Cervantes; Guido Finazzi; Martin Griesshammer; Claire Harrison; Hans Carl Hasselbalch; Rudiger Hehlmann; Ronald Hoffman; Jean-Jacques Kiladjian; Nicolaus Kröger; Ruben Mesa; Mary F McMullin; Animesh Pardanani; Francesco Passamonti; Alessandro M Vannucchi; Andreas Reiter; Richard T Silver; Srdan Verstovsek; Ayalew Tefferi
Journal:  J Clin Oncol       Date:  2011-01-04       Impact factor: 44.544

Review 4.  Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet.

Authors:  Tiziano Barbui; Ayalew Tefferi; Alessandro M Vannucchi; Francesco Passamonti; Richard T Silver; Ronald Hoffman; Srdan Verstovsek; Ruben Mesa; Jean-Jacques Kiladjian; Rȕdiger Hehlmann; Andreas Reiter; Francisco Cervantes; Claire Harrison; Mary Frances Mc Mullin; Hans Carl Hasselbalch; Steffen Koschmieder; Monia Marchetti; Andrea Bacigalupo; Guido Finazzi; Nicolaus Kroeger; Martin Griesshammer; Gunnar Birgegard; Giovanni Barosi
Journal:  Leukemia       Date:  2018-02-27       Impact factor: 11.528

5.  Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia.

Authors:  Naval Daver; Aditi Shastri; Tapan Kadia; Kate Newberry; Naveen Pemmaraju; Elias Jabbour; Linghsa Zhou; Sherry Pierce; Jorge Cortes; Hagop Kantarjian; Srdan Verstovsek
Journal:  Leuk Res       Date:  2014-07-06       Impact factor: 3.156

Review 6.  Allogeneic stem cell transplant for myelofibrosis patients over age 60: likely impact of the JAK2 inhibitors.

Authors:  V Fauble; J Leis; R A Mesa
Journal:  Leuk Suppl       Date:  2012-05-09

Review 7.  New Strategies in Myeloproliferative Neoplasms: The Evolving Genetic and Therapeutic Landscape.

Authors:  Ami B Patel; Nadeem A Vellore; Michael W Deininger
Journal:  Clin Cancer Res       Date:  2016-03-01       Impact factor: 12.531

8.  Modest activity of pomalidomide in patients with myelofibrosis and significant anemia.

Authors:  Naval Daver; Aditi Shastri; Tapan Kadia; Alfonso Quintas-Cardama; Elias Jabbour; Marina Konopleva; Susan O'Brien; Sherry Pierce; Lingsha Zhou; Jorge Cortes; Hagop Kantarjian; Srdan Verstovsek
Journal:  Leuk Res       Date:  2013-07-25       Impact factor: 3.156

Review 9.  The new landscape of therapy for myelofibrosis.

Authors:  Krisstina Gowin; Robyn Emanuel; Holly Geyer; Ruben A Mesa
Journal:  Curr Hematol Malig Rep       Date:  2013-12       Impact factor: 3.952

10.  Megakaryocyte TGFβ1 partitions erythropoiesis into immature progenitor/stem cells and maturing precursors.

Authors:  Silvana Di Giandomenico; Pouneh Kermani; Nicole Mollé; Maria Mia Yabut; Ghaith Abu-Zeinah; Thomas Stephens; Nassima Messali; Ryan Schreiner; Fabienne Brenet; Shahin Rafii; Joseph M Scandura
Journal:  Blood       Date:  2020-08-27       Impact factor: 22.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.